Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC.
Pinto C, Normanno N, Orlandi A, Fenizia F, Damato A, Maiello E, Tamburini E, Di Costanzo F, Tonini G, Bilancia D, Corsi D, Pisconti S, Ferrau F, Gori S, Daniele B, Zaniboni A, Soto Parra H, Frassinetti GL, Iaffaioli RV, Cassata A, Zampino MG, Repetto L, Calegari MA, Barone C; all the investigators of ERMES study group..
Pinto C, et al. Among authors: repetto l.
Future Oncol. 2018 Jun;14(14):1339-1346. doi: 10.2217/fon-2017-0592. Epub 2018 May 30.
Future Oncol. 2018.
PMID: 29846100
Clinical Trial.